KLK3 and neoplasm: The risk stratification system, proposed by D’Amico et al. in 1998, classifies patients into low-, intermediate-, and high-risk (HR) groups based on clinical tumor stage (cT), prostate-specific antigen (PSA) level, and biopsy Grade Group (GG) at diagnosis [1].